KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study
详细信息 查看全文
- 作者：Ronan T. Swords ; MD ; PhD ; FRCPI ; FRCPatha ; rswords@med.miami.edu" class="auth_mail" title="E-mail the corresponding author ; Peter L. Greenberg ; MDb ; Andrew H. Wei ; MBBS ; PhDc ; Simon Durrant ; MBBS ; MRCS ; LRCP ; FRCP ; FRCPathd ; Anjali S. Advani ; MDe ; Mark S. Hertzberg ; MBBS ; PhD ; FRACP ; FRCPAf ; Ian D. Lewis ; MBBS ; PhDg ; Gabriel Rivera ; MDb ; Dita Gratzinger ; MD ; PhDb ; Alice C. Fan ; MDb ; Dean W. Felsher ; MD ; PhDb ; Jorge E. Cortes ; MDh ; Justin M. Watts ; MDa ; Geoff T. Yarranton ; PhDi ; Jackie M. Walling ; MB ; ChB ; PhDi ; Jeffrey E. Lancet ; MDj
- 关键词：KB004 ; Myelodysplastic syndromes ; Acute myeloid leukemia ; Myelofibrosis ; Ephrin receptor tyrosine kinase ; EphA3
- 刊名：Leukemia Research
- 出版年：2016
- 出版时间：November 2016
- 年：2016
- 卷：50
- 期：Complete
- 页码：123-131
- 全文大小：2114 K
文摘
- •
KB004 is a novel anti-ephrin novel monoclonal antibody targeting EphA3.
- •
KB004 was safe and relatively well-tolerated in patients with myeloid neoplasms.
- •
Manageable infusion reactions were dose limiting.
- •
There was clinical activity in patients with fibrotic MDS and myelofibrosis.